Ann: Letter to Shareholders, page-185

Bit225 has undergone many many trials for HCV and HIV.
Patient safety is clearly not an issue.
They have piles of BIT225 data to plop onto the FDA assessor desk....immediately

From the recent Letter ...

>Oneof the main focuses of the international medical field is how toinduce the body’s immune system to work more >efficiently, so thatit will seek out and destroy hidden viruses.

>Thereason why Biotron is so encouraged by the results of the 009 HIV‐1phase 2 trial is because the trial data >indicate that BIT225 inducessuch a desired immune response. This effect is additional to thetargeting by BIT225 of >virus in macrophage cells.

My summary...

HIV leads to immune system exhaustion.
Bit225 treatment is believed to lead to Immune system recovery for HIV patients. The immune response change.
This is beneficial to any HIV patient.


One can deduce....Bit225 works by eradicating the root cause....HIV in the reservoir cells....which is different to the standard ART drugs.


Bit225 Is safe. Bit225 is additional benefit to HIV patients on ART.
FDA ...here we come.

GLA BIT holders